Drug Registration and Acceptance

Drug Name

Exact

Active Ingredient

Acceptance No.

Manufacturers

Acceptance Date

Status Date

Classification

Review Status

Drug Type

Submission

Evaluation Conclusion

ATC Category

Special Approval Varieties

Task Type

Major Special Varieties

Sequence No.

Stock Code

Visualized Analysis Export Evaluation Conclusion Evaluation Progress

Acceptance No.	Drug Name	Active Ingredient	Dosage Form	Classification	Submission	Acceptance Date	Manufacturers	Review Status	Status Date	View
JYSB2500007	注射用重组人凝血因子Ⅸ	Recombinant Coagulation Factor Ⅸ	Lyophilized	Biological Products	Supplementary Application	2025-01-04	Pfizer Europe Ma Eeig;Wyeth Farma SA			view
JYSB2500006	注射用重组人凝血因子Ⅸ	Recombinant Coagulation Factor Ⅸ	Lyophilized	Biological Products	Supplementary Application	2025-01-04	Pfizer Europe Ma Eeig;Wyeth Farma SA			view
JYSB2500004	注射用重组人凝血因子Ⅸ	Recombinant Coagulation Factor Ⅸ	Lyophilized	Biological Products	Supplementary Application	2025-01-04	Pfizer Europe Ma Eeig;Wyeth Farma SA			view
JYSB2500005	注射用重组人凝血因子Ⅸ	Recombinant Coagulation Factor Ⅸ	Lyophilized	Biological Products	Supplementary Application	2025-01-04	Pfizer Europe Ma Eeig;Wyeth Farma SA			view
JYSZ2200033	注射用重组人凝血因子Ⅸ	Recombinant Coagulation Factor Ⅸ	Lyophilized	Biological Products	License Renew	2022-07-21	Pfizer Europe Ma Eeig;Wyeth Farma SA;Pfizer Investment Co Ltd			view
JYSZ2200036	注射用重组人凝血因子Ⅸ	Recombinant Coagulation Factor Ⅸ	Lyophilized	Biological Products	License Renew	2022-07-21	Pfizer Europe Ma Eeig;Wyeth Farma SA;Pfizer Investment Co Ltd			view
JYSZ2200035	注射用重组人凝血因子Ⅸ	Recombinant Coagulation Factor Ⅸ	Lyophilized	Biological Products	License Renew	2022-07-21	Pfizer Europe Ma Eeig;Wyeth Farma SA;Pfizer Investment Co Ltd			view
JYSZ2200034	注射用重组人凝血因子Ⅸ	Recombinant Coagulation Factor Ⅸ	Lyophilized	Biological Products	License Renew	2022-07-21	Pfizer Europe Ma Eeig;Wyeth Farma SA;Pfizer Investment Co Ltd			view
JXSL2200118	注射用重组人凝血因子IX-白蛋白融合蛋白		Lyophilized	Biological Products(3.1)	Import Drug Application	2022-07-11	Parexel China Co Ltd;Csl Behring GmbH			view
JXSL2200115	注射用重组人凝血因子IX-白蛋白融合蛋白		Lyophilized	Biological Products(3.1)	Import Drug Application	2022-07-11	Parexel China Co Ltd;Csl Behring GmbH			view
JXSL2200114	注射用重组人凝血因子IX-白蛋白融合蛋白		Lyophilized	Biological Products(3.1)	Import Drug Application	2022-07-11	Parexel China Co Ltd;Csl Behring GmbH			view
JXSL2200117	注射用重组人凝血因子IX-白蛋白融合蛋白		Lyophilized	Biological Products(3.1)	Import Drug Application	2022-07-11	Parexel China Co Ltd;Csl Behring GmbH			view
JXSL2200116	注射用重组人凝血因子IX-白蛋白融合蛋白		Lyophilized	Biological Products(3.1)	Import Drug Application	2022-07-11	Parexel China Co Ltd;Csl Behring GmbH			view
JYSB2101102	注射用重组人凝血因子IX	Recombinant Coagulation Factor Ⅸ	Lyophilized	Biological Products	Supplementary Application	2021-08-10	Pfizer Europe Ma Eeig;Wyeth Farma SA			view
JYSB2101103	注射用重组人凝血因子IX	Recombinant Coagulation Factor Ⅸ	Lyophilized	Biological Products	Supplementary Application	2021-08-10	Pfizer Europe Ma Eeig;Wyeth Farma SA			view
JYSB2101100	注射用重组人凝血因子IX	Recombinant Coagulation Factor Ⅸ	Lyophilized	Biological Products	Supplementary Application	2021-08-10	Pfizer Europe Ma Eeig;Wyeth Farma SA			view
JYSB2101101	注射用重组人凝血因子IX	Recombinant Coagulation Factor Ⅸ	Lyophilized	Biological Products	Supplementary Application	2021-08-10	Pfizer Europe Ma Eeig;Wyeth Farma SA			view
JYSB2100046	注射用重组人凝血因子Ⅸ	Recombinant Coagulation Factor Ⅸ	Lyophilized	Biological Products	Supplementary Application	2021-02-19	Pfizer Europe Ma Eeig;Wyeth Farma SA	In Review	2021-02-18	view
JYSB2100045	注射用重组人凝血因子Ⅸ	Recombinant Coagulation Factor Ⅸ	Lyophilized	Biological Products	Supplementary Application	2021-02-19	Pfizer Europe Ma Eeig;Wyeth Farma SA	In Review	2021-02-18	view
JYSB2100048	注射用重组人凝血因子Ⅸ	Recombinant Coagulation Factor Ⅸ	Lyophilized	Biological Products	Supplementary Application	2021-02-19	Pfizer Europe Ma Eeig;Wyeth Farma SA	In Review	2021-02-18	view